Opinion|Videos|January 9, 2024
Identifying the Right CDMO to Support Biopharma Manufacturing
Author(s)Ascendia Pharma
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals discusses:
- What to look for when identifying a CDMO for a drug development project
- Ascendia Pharmaceuticals and its expansion of manufacturing services
- Ascendia Pharmaceuticals as a "Partner of Choice"
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Rare Disease Treatments: Navigating the Economics of Global Innovation
2
WEF Welcomes ACG Shirwal as First Pharma Packaging Site in Global Lighthouse Network
3
Women in STEM: Early Phase Drug Development
4
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
5